
WHAT IS CLAIMED IS:

1. A compound of structural Formula I:



I

or a pharmaceutically acceptable salt thereof, wherein

T is independently selected from the group: CR^3 and N, provided that one or two of T, U, V and W are N;

U is independently selected from the group:

1) CR^4, and
2) N;

V is independently selected from the group:

1) CR^5, and
2) N;

W is independently selected from the group:

1) CR^6, and
2) N;

R^1 is selected from the group:

1) morpholine,
2) thiomorpholine,
3) piperidine,
4) pyrrolidine,
5) tetrahydropyran,
6) octahydro-1H-pyrrolo[2,3-c]pyridine,
7) 3-azabicyclo[3.1.0]hexane,

8) 5-azaspiro[2.4]heptane,

9) 1-oxa-7-azaspiro[4.4]nonane,

10) 1-oxa-8-azaspiro[4.5]decane,

11) 3-oxa-1,8-diazaspiro[4.5]decane,

12) 2,8-diazaspiro[4.5]decane,

13) 1-oxa-3,8-diazaspiro[4.5]decane,

14) 2-oxa-8-azaspiro[4.5]decane,

15) 1,8-diazaspiro[4.5]decane, and

16) 1-oxa-4,9-diazaspiro[5.5]undecane,

wherein R^1 is unsubstituted or substituted with one to six substituents selected from R^a;

R^2 is selected from the group:

1) aryl, and

2) heteroaryl,

wherein R^2 is unsubstituted or substituted with one to five substituents selected from R^b;

R^3 is selected from the group:

1) hydrogen,

2) OH,

3) CN,

4) CF_3,

5) CF_2H,

6) -C_{1-6}alkyl,

7) -O-C_{1-6}alkyl,

8) halogen, and

9) -C_{1-6}alkyl-O-C_{1-6}alkyl,

wherein R^3 is unsubstituted or substituted with one to five substituents selected from R^d;

R^4 is selected from the group:

1) hydrogen,

2) OH,

3) CN,

4) CF_3,

5) CF_2H,

6) -C_{1-6}alkyl,

7) -O-C_{1-6}alkyl,

8) halogen,

9) -C_{3-6}cycloalkyl,

10) -C_{2-6}cycloheteroalkyl, and

11) -C_{1-6}alkyl-O-C_{1-6}alkyl,

wherein R^4 is unsubstituted or substituted with one to five substituents selected from R^e;

R^5 is selected from the group:

1) hydrogen,

2) OH,

3) CN,

4) CF_3,

5) CF_2H,

6) -C_{1-6}alkyl,

7) -O-C_{1-6}alkyl,

8) halogen,

9) -C_{3-6}cycloalkyl,

10) -C_{2-6}cycloheteroalkyl, and

11) -C_{1-6}alkyl-O-C_{1-6}alkyl,

wherein R^5 is unsubstituted or substituted with one to five substituents selected from R^f;

R^6 is selected from the group:

1) hydrogen,

2) OH,

3) CN,

4) CF_3,

5) CF_2H,

6) -C_{1-6}alkyl,

7) -O-C_{1-6}alkyl,

8) halogen,

9) -C_{3-6}cycloalkyl,

10) -C_{2-6}cycloheteroalkyl, and

11) -C_{1-6}alkyl-O-C_{1-6}alkyl,

wherein R^6 is unsubstituted or substituted with one to five substituents selected from Rg;

each R^a is independently selected from the group:

1) CN,

2) oxo,

3) -OH,

4) halogen,

5) -C_{1-6}alkyl,

6) -O-C_{1-6}alkyl,

7) -C_{2-6}alkenyl,

8) -C_{2-6}alkynyl,

9) -C_{3-6}cycloalkyl,

10) -C_{2-6}cycloheteroalkyl,

11) aryl,

12) heteroaryl, and

13) -C(O)C_{1-6}alkyl,

wherein each R^a is unsubstituted or substituted with one to six substituents selected from halogen, CF_3, OH, C_{1-6}alkyl, and -OC_{1-6}alkyl;

each R^b is independently selected from the group:

1) CN,

2) -OH,

3) -CH_3,

4) -CF_3,

5) -CF_2H,

6) -OCF_2H, and

7) cyclopropane,

wherein each R^b is unsubstituted or substituted with one to six substituents selected from halogen, CF_3, CF_2H, OCF_3, CN, CH_2CF_3, CF_2CH_3, -C_{1-6}alkyl, and -OC_{1-6}alkyl;

each R^d is independently selected from the group:

1) CF_3,

2) halogen, and

3) -C_{1-6}alkyl,

wherein alkyl is unsubstituted or substituted with one to three substituents selected from: CF_3, halogen, OH and -OC_{1-6}alkyl;

each R^e is independently selected from the group:

1) CF_3,

2) halogen, and

3) -C_{1-6}alkyl,

wherein alkyl is unsubstituted or substituted with one to three substituents selected from: CF_3, halogen, OH and -OC_{1-6}alkyl;

each R^f is independently selected from the group:

1) CF_3,

2) halogen, and

3) -C_{1-6}alkyl,

wherein alkyl is unsubstituted or substituted with one to three substituents selected from: CF_3, halogen, OH and -OC_{1-6}alkyl; and

each R^g is independently selected from the group:

1) CF_3,

2) halogen, and

3) -C_{1-6}alkyl,

wherein alkyl is unsubstituted or substituted with one to three substituents selected from: CF_3, halogen, OH and -OC_{1-6}alkyl.

2. The compound according to Claim 1 wherein W is CR^6; or a pharmaceutically acceptable salt thereof.

3. The compound according to Claim 1 wherein

R^1 is selected from the group:

1) morpholine,
2) piperidine,
3) pyrrolidine,
4) tetrahydropyran, and
5) octahydro-1H-pyrrolo[2,3-c]pyridine,

wherein R^1 is unsubstituted or substituted with one to six substituents selected from R^a;
or a pharmaceutically acceptable salt thereof.

4. The compound according to Claim 1 wherein

R^1 is selected from the group:

1) morpholine,
2) pyrrolidine,
3) tetrahydropyran, and
4) octahydro-1H-pyrrolo[2,3-c]pyridine,

wherein R^1 is unsubstituted or substituted with one to six substituents selected from R^a;
or a pharmaceutically acceptable salt thereof.

5. The compound according to Claim 1 wherein R^2 is heteroaryl, wherein heteroaryl is unsubstituted or substituted with one to five substituents selected from R^b; or a pharmaceutically acceptable salt thereof.

6. The compound according to Claim 1 wherein R^2 is aryl, wherein aryl is substituted with two to five substituents selected from R^b;
or a pharmaceutically acceptable salt thereof.

7. The compound according to Claim 1 wherein R^3 is selected from the group:

1) hydrogen, and
2) $-C_{1-6}$alkyl,

wherein R^3 is unsubstituted or substituted with one to five substituents selected from R^d;
or a pharmaceutically acceptable salt thereof.

8. The compound according to Claim 1 wherein R^3 is hydrogen; or a pharmaceutically acceptable salt thereof.

9. The compound according to Claim 1 wherein R^4 is selected from the group:

1) hydrogen,
2) OH,
3) CN,
4) CF_3,
5) CF_2H,
6) -C_{1-6}alkyl,
7) -O-C_{1-6}alkyl,
8) halogen, and
9) -C_{1-6}alkyl-O-C_{1-6}alkyl,

wherein R^4 is unsubstituted or substituted with one to five substituents selected from R^e; or a pharmaceutically acceptable salt thereof.

10. The compound according to Claim 1 wherein R^4 is selected from the group:

1) hydrogen, and
2) -C_{1-6}alkyl,

wherein R^4 is unsubstituted or substituted with one to five substituents selected from R^e; or a pharmaceutically acceptable salt thereof.

11. The compound according to Claim 1 wherein R^5 is selected from the group:

1) hydrogen,
2) OH,
3) CN,
4) CF_3,
5) CF_2H,
6) -C_{1-6}alkyl,
7) -O-C_{1-6}alkyl,
8) halogen, and
9) -C_{1-6}alkyl-O-C_{1-6}alkyl,

wherein R^5 is unsubstituted or substituted with one to five substituents selected from R^f; or a pharmaceutically acceptable salt thereof.

12. The compound according to Claim 1 wherein R^5 is selected from the group:

1) hydrogen,
2) -C_{1-6}alkyl, and
3) halogen,

wherein R^5 is unsubstituted or substituted with one to five substituents selected from R^f; or a pharmaceutically acceptable salt thereof.

13. The compound according to Claim 1 wherein R^6 is selected from the group:

1) hydrogen,
2) -C_{1-6}alkyl, and
3) -O-C_{1-6}alkyl,

wherein R^6 is unsubstituted or substituted with one to five substituents selected from R^g; or a pharmaceutically acceptable salt thereof.

14. The compound according to Claim 1 wherein R^6 is hydrogen; or a pharmaceutically acceptable salt thereof.

15. The compound according to Claim 1 wherein

R^2 is heteroaryl, wherein R^2 is unsubstituted or substituted with one to five substituents selected from R^b;

R^3 is selected from the group:

1) hydrogen, and
2) -C_{1-6}alkyl,

wherein R^3 is unsubstituted or substituted with one to five substituents selected from R^d;

R^4 is selected from the group:

1) hydrogen,
2) OH,

3) CN,

4) CF_3,

5) CF_2H,

6) -C_{1-6}alkyl,

7) -O-C_{1-6}alkyl,

8) halogen, and

9) -C_{1-6}alkyl-O-C_{1-6}alkyl,

wherein R^4 is unsubstituted or substituted with one to five substituents selected from R^e;

R^5 is selected from the group:

1) hydrogen,

2) OH,

3) CN,

4) CF_3,

5) CF_2H,

6) -C_{1-6}alkyl,

7) -O-C_{1-6}alkyl,

8) halogen, and

9) -C_{1-6}alkyl-O-C_{1-6}alkyl,

wherein R^5 is unsubstituted or substituted with one to five substituents selected from R^f; and

R^6 is selected from the group:

1) hydrogen,

2) -C_{1-6}alkyl, and

3) -O-C_{1-6}alkyl,

wherein R^6 is unsubstituted or substituted with one to five substituents selected from R^g;

or a pharmaceutically acceptable salt thereof.

16. The compound according to Claim 1 wherein

W is CR^6;

R^2 is aryl, wherein aryl is substituted with two to five substituents selected from R^b;

R^3 is hydrogen;

R^4 is selected from the group:

1) hydrogen, and
2) -C_{1-6}alkyl,

wherein R^4 is unsubstituted or substituted with one to five substituents selected from R^e;

R^5 is selected from the group:

1) hydrogen,
2) -C_{1-6}alkyl, and
3) halogen,

wherein R^5 is unsubstituted or substituted with one to five substituents selected from R^f; and

R^6 is hydrogen;

or a pharmaceutically acceptable salt thereof.

17. A compound selected from:

1) (*S*)-1-(4-(2-hydroxy-4-(trifluoromethyl)phenyl)pyrido[3,4-*d*]pyridazin-1-yl)-3-methylpyrrolidin-3-ol;
2) (*S*)-1-(1-(2-hydroxy-4-(trifluoromethyl)phenyl)pyrido[3,4-*d*]-pyridazin-4-yl)-3-methylpyrrolidin-3-ol;
3) (*cis*)-4-(5-(2-(difluoromethoxy)-4-(trifluoromethyl)phenyl)pyrido[2,3-*d*]pyridazin-8-yl)-2,6-dimethylmorpholine;
4) 2-(4-((*cis*)-2,6-dimethylmorpholino)pyrido[3,4-*d*]pyridazin-1-yl)-5-(trifluoromethyl)phenol;
5) 2-(1-((*cis*)-2,6-dimethylmorpholino)pyrido[3,4-*d*]pyridazin-4-yl)-5-(trifluoromethyl)phenol;
6) 2-(5-((*cis*)-2,6-dimethylmorpholino)pyrido[2,3-*d*]pyridazin-8-yl)-5-(trifluoromethyl)phenol;
7) (*cis*)-4-(1-(2-(difluoromethoxy)-4-(trifluoromethyl)phenyl)pyrido[3,4-*d*]pyridazin-4-yl)-2,6-dimethylmorpholine;

8) 2-(8-((*cis*)-2,6-dimethylmorpholino)pyridazino[4,5-*c*]pyridazin-5-yl)-5-(trifluoromethyl)-phenol;

9) 2-(4-((*cis*)-2,6-dimethylmorpholino)pyridazino[4,5-*d*]pyridazin-1-yl)-5-(trifluoromethyl)-phenol;

10) (*S*)-1-(5-(2-hydroxy-4-(trifluoromethyl)phenyl)-2-methylpyrido[2,3-*d*]pyridazin-8-yl)-3-methylpyrrolidin-3-ol;

11) (*cis*)-4-(1-(benzofuran-5-yl)pyrido[3,4-*d*]pyridazin-4-yl)-2,6-dimethylmorpholine;

12) (*S*)-1-(5-(2-hydroxy-4-(trifluoromethyl)phenyl)-2-(trifluoromethyl)pyrido[2,3-*d*]pyridazin-8-yl)-3-methylpyrrolidin-3-ol;

13) (3*S*,4*s*,5*R*)-1-(4-(2-hydroxy-4-(trifluoromethyl)phenyl)pyridazino[4,5-*d*]pyridazin-1-yl)-3,4,5-trimethylpiperidin-4-ol;

14) 2-(4-((*cis*)-2,6-dimethylmorpholino)-5-methylphthalazin-1-yl)-5-(trifluoromethyl)phenol;

15) 2-(4-((*cis*)-2,6-dimethylmorpholino)-8-methylphthalazin-1-yl)-5-(trifluoromethyl)phenol;

16) (3*S*,4*s*,5*R*)-1-(1-(2-hydroxy-4-(trifluoromethyl)phenyl)pyrido[3,4-*d*]pyridazin-4-yl)-3,4,5-trimethylpiperidin-4-ol;

17) (3*S*,4*s*,5*R*)-1-(4-(2-hydroxy-4-(trifluoromethyl)phenyl)pyrido[3,4-*d*]pyridazin-1-yl)-3,4,5-trimethylpiperidin-4-ol;

18) (3*S*,4*r*,5*R*)-1-(1-(2-hydroxy-4-(trifluoromethyl)phenyl)pyrido[3,4-*d*]pyridazin-4-yl)-3,5-dimethylpiperidin-4-ol;

19) (3*S*,4*r*,5*R*)-1-(4-(2-hydroxy-4-(trifluoromethyl)phenyl)pyrido[3,4-*d*]pyridazin-1-yl)-3,5-dimethylpiperidin-4-ol;

20) 2-(4-((*cis*)-2,6-dimethylmorpholino)-6-methylphthalazin-1-yl)-5-(trifluoromethyl)phenol;

21) 2-(4-((*cis*)-2,6-dimethylmorpholino)-7-methylphthalazin-1-yl)-5-(trifluoromethyl)phenol;

22) (*S*)-1-(5-(2-hydroxy-4-(trifluoromethyl)phenyl)pyrido[2,3-*d*]-pyridazin-8-yl)-3-methylpyrrolidin-3-ol;

23) 2-(8-((3a*S*,7a*R*)-6-methyloctahydro-1H-pyrrolo[2,3-*c*]pyridin-1-yl)pyrido[2,3-*d*]pyridazin-5-yl)-5-(trifluoromethyl)phenol;

24) (3*S*,4*s*,5*R*)-1-(5-(2-hydroxy-4-(trifluoromethyl)phenyl)pyrido[2,3-*d*]pyridazin-8-yl)-3,4,5-trimethylpiperidin-4-ol;

25) 8-(5-(2-hydroxy-4-(trifluoromethyl)phenyl)pyrido[2,3-*d*]pyridazin-8-yl)-3-oxa-1,8-diazaspiro[4.5]decan-2-one;

26) (*cis*)-4-(5-(2-hydroxy-4-(trifluoromethyl)phenyl)pyrido[2,3-*d*]pyridazin-8-yl)-2,6-dimethylthiomorpholine 1,1-dioxide;

27) (*R*)-1-(5-(2-hydroxy-4-(trifluoromethyl)phenyl)pyrido[2,3-*d*]pyridazin-8-yl)-3-(trifluoromethyl)pyrrolidin-3-ol;

28) (*S*)-1-(5-(2-hydroxy-4-(trifluoromethyl)phenyl)pyrido[2,3-*d*]pyridazin-8-yl)-3-(trifluoromethyl)pyrrolidin-3-ol;

29) (*R*)-3-(difluoromethyl)-1-(5-(2-hydroxy-4-(trifluoromethyl)phenyl)pyrido[2,3-*d*]pyridazin-8-yl)pyrrolidin-3-ol;

30) (*S*)-3-(difluoromethyl)-1-(5-(2-hydroxy-4-(trifluoromethyl)phenyl)pyrido[2,3-*d*]pyridazin-8-yl)pyrrolidin-3-ol;

31) (*R*)-2-(8-(1-oxa-7-azaspiro[4.4]nonan-7-yl)pyrido[2,3-*d*]pyridazin-5-yl)-5-(trifluoromethyl)phenol;

32) (*S*)-2-(8-(1-oxa-7-azaspiro[4.4]nonan-7-yl)pyrido[2,3-*d*]pyridazin-5-yl)-5-(trifluoromethyl)phenol;

33) 2-(8-(1-oxa-8-azaspiro[4.5]decan-8-yl)pyrido[2,3-*d*]pyridazin-5-yl)-5-(trifluoromethyl)phenol;

34) 2-(8-(2-oxa-8-azaspiro[4.5]decan-8-yl)pyrido[2,3-*d*]pyridazin-5-yl)-5-(trifluoromethyl)phenol;

35) 9-(5-(2-hydroxy-4-(trifluoromethyl)phenyl)pyrido[2,3-*d*]pyridazin-8-yl)-1-oxa-4,9-diazaspiro[5.5]undecan-3-one;

36) 2-(8-((*cis*)-4,4-difluoro-3,5-dimethylpiperidin-1-yl)pyrido[2,3-*d*]pyridazin-5-yl)-5-(trifluoromethyl)phenol;

37) 1-(8-(5-(2-hydroxy-4-(trifluoromethyl)phenyl)pyrido[2,3-*d*]pyridazin-8-yl)-1,8-diazaspiro[4.5]decan-1-yl)ethan-1-one;

38) 1-(8-(5-(2-hydroxy-4-(trifluoromethyl)phenyl)pyrido[2,3-*d*]pyridazin-8-yl)-2,8-diazaspiro[4.5]decan-2-yl)ethan-1-one;

39) 8-(5-(2-hydroxy-4-(trifluoro-methyl)phenyl)pyrido[2,3-*d*]-pyridazin-8-yl)-3-methyl-1-oxa-3,8-diazaspiro[4.5]decan-2-one;

40) 2-(8-(4,4-dimethyl-1-oxa-8-azaspiro[4.5]decan-8-yl)pyrido[2,3-*d*]pyridazin-5-yl)-5-(trifluoromethyl)phenol;

41) (*R*)-1-(5-(2-hydroxy-4-(trifluoromethyl)phenyl)pyrido[2,3-*d*]pyridazin-8-yl)-3-phenylpyrrolidin-3-ol;

42) (*S*)-1-(5-(2-hydroxy-4-(trifluoromethyl)phenyl)pyrido[2,3-*d*]pyridazin-8-yl)-3-phenylpyrrolidin-3-ol;

43) 8-(5-(2-hydroxy-4-(trifluoromethyl)phenyl)pyrido[2,3-*d*]pyridazin-8-yl)-1-methyl-1,8-diazaspiro[4.5]decan-2-one;

44) 8-(5-(2-hydroxy-4-(trifluoromethyl)phenyl)pyrido[2,3-*d*]pyridazin-8-yl)-1-oxa-3,8-diazaspiro[4.5]decan-2-one;

45) 2-(8-(6,6-difluoro-3-azabicyclo[3.1.0]hexan-3-yl)pyrido[2,3-*d*]pyridazin-5-yl)-5-(trifluoromethyl)phenol;

46) 8-(5-(2-hydroxy-4-(trifluoromethyl)phenyl)pyrido[2,3-*d*]pyridazin-8-yl)-1-oxa-8-azaspiro[4.5]decan-2-one;

47) (*R*)-4,4-difluoro-1-(5-(2-hydroxy-4-(trifluoromethyl)phenyl)pyrido[2,3-*d*]pyridazin-8-yl)pyrrolidin-3-ol;

48) (*S*)-4,4-difluoro-1-(5-(2-hydroxy-4-(trifluoromethyl)phenyl)pyrido[2,3-*d*]pyridazin-8-yl)pyrrolidin-3-ol;

49) (*R*)-5-(5-(2-hydroxy-4-(trifluoromethyl)phenyl)pyrido[2,3-*d*]pyridazin-8-yl)-5-azaspiro[2.4]heptan-7-ol;

50) (*S*)-5-(5-(2-hydroxy-4-(trifluoromethyl)phenyl)pyrido[2,3-*d*]pyridazin-8-yl)-5-azaspiro[2.4]heptan-7-ol;

51) (*R*)-3-cyclopropyl-1-(5-(2-hydroxy-4-(trifluoromethyl)phenyl)pyrido[2,3-*d*]pyridazin-8-yl)pyrrolidin-3-ol;

52) (*S*)-3-cyclopropyl-1-(5-(2-hydroxy-4-(trifluoromethyl)phenyl)pyrido[2,3-*d*]pyridazin-8-yl)pyrrolidin-3-ol;

53) (*R*)-3-((dimethylamino)methyl)-1-(5-(2-hydroxy-4-(trifluoromethyl)phenyl)pyrido-[2,3-*d*]pyridazin-8-yl)pyrrolidin-3-ol;

54) (*S*)-3-((dimethylamino)methyl)-1-(5-(2-hydroxy-4-(trifluoromethyl)phenyl)pyrido-[2,3-*d*]pyridazin-8-yl)pyrrolidin-3-ol;

55) (*R*)-3-ethyl-1-(5-(2-hydroxy-4-(trifluoromethyl)phenyl)pyrido[2,3-*d*]pyridazin-8-yl)-pyrrolidin-3-ol;

56) (*S*)-3-ethyl-1-(5-(2-hydroxy-4-(trifluoromethyl)phenyl)pyrido[2,3-*d*]pyridazin-8-yl)-pyrrolidin-3-ol;

57) (*R*)-2-(8-(3-(hydroxymethyl)-3-methylpyrrolidin-1-yl)pyrido[2,3-*d*]pyridazin-5-yl)-5-(trifluoromethyl)phenol;

58) (*S*)-2-(8-(3-(hydroxymethyl)-3-methylpyrrolidin-1-yl)pyrido[2,3-*d*]pyridazin-5-yl)-5-(trifluoromethyl)phenol;

59) (*R*)-2-(8-(3-(2-hydroxypropan-2-yl)pyrrolidin-1-yl)pyrido[2,3-*d*]pyridazin-5-yl)-5-(trifluoromethyl)phenol;

60) (*S*)-2-(8-(3-(2-hydroxypropan-2-yl)pyrrolidin-1-yl)pyrido[2,3-*d*]pyridazin-5-yl)-5-(trifluoromethyl)phenol;

61) 2-(8-((2*R*,6*R*)-2-(hydroxymethyl)-6-methylmorpholino)pyrido[2,3-*d*]pyridazin-5-yl)-5-(trifluoromethyl)phenol;

62) 2-(8-((2*S*,6*S*)-2-(hydroxymethyl)-6-methylmorpholino)pyrido[2,3-*d*]pyridazin-5-yl)-5-(trifluoromethyl)phenol;

63) 2-(8-((2*S*,6*S*)-2-(hydroxymethyl)-6-methylmorpholino)pyrido[2,3-*d*]pyridazin-5-yl)-5-(trifluoromethyl)phenol;

64) 2-(8-((2*R*,6*R*)-2-(hydroxymethyl)-6-methylmorpholino)pyrido[2,3-*d*]pyridazin-5-yl)-5-(trifluoromethyl)phenol;

65) 1-((2*R*,4*r*,6*S*)-2,6-dimethyltetrahydro-2H-pyran-4-yl)-4-(2-methyl-4(trifluoromethyl)-phenyl)phthalazine;

66) (2*R*,4*s*,6*S*)-4-(5-(2-hydroxy-4-(trifluoromethyl)phenyl)pyrido[2,3-*d*]-pyridazin-8-yl)-2,6-dimethyltetrahydro-2*H*-pyran-4-ol;

67) (2*R*,4*r*,6*S*)-4-(5-(2-hydroxy-4-(trifluoromethyl)phenyl)pyrido[2,3-*d*]-pyridazin-8-yl)-2,6-dimethyltetrahydro-2*H*-pyran-4-ol;

68) (*S*)-1-(2-(difluoromethyl)-5-(2-hydroxy-4-(trifluoromethyl)phenyl)pyrido[2,3-*d*]pyridazin-8-yl)-3-methylpyrrolidin-3-ol; and

69) (*S*)-1-(3-(difluoromethyl)-5-(2-hydroxy-4-(trifluoromethyl)phenyl)pyrido[2,3-*d*]pyridazin-8-yl)-3-methylpyrrolidin-3-ol;

or a pharmaceutically acceptable salt thereof.

18. A compound selected from:

1) (*S*)-1-(4-(2-hydroxy-4-(trifluoromethyl)phenyl)pyrido[3,4-*d*]pyridazin-1-yl)-3-methylpyrrolidin-3-ol;

2) (*S*)-1-(1-(2-hydroxy-4-(trifluoromethyl)phenyl)pyrido[3,4-*d*]-pyridazin-4-yl)-3-methylpyrrolidin-3-ol;

3) 2-(4-((*cis*)-2,6-dimethylmorpholino)pyridazino[4,5-*d*]pyridazin-1-yl)-5-(trifluoromethyl)phenol;

4) (*S*)-1-(5-(2-hydroxy-4-(trifluoromethyl)phenyl)pyrido[2,3-*d*]-pyridazin-8-yl)-3-methylpyrrolidin-3-ol;

5) 2-(8-((3a*S*,7a*R*)-6-methyloctahydro-1H-pyrrolo[2,3-*c*]pyridin-1-yl)pyrido[2,3-*d*]pyridazin-5-yl)-5-(trifluoromethyl)phenol;

6) (2*R*,4*s*,6*S*)-4-(5-(2-hydroxy-4-(trifluoromethyl)phenyl)pyrido[2,3-*d*]-pyridazin-8-yl)-2,6-dimethyltetrahydro-2*H*-pyran-4-ol; and

7) (2*R*,4*r*,6*S*)-4-(5-(2-hydroxy-4-(trifluoromethyl)phenyl)pyrido[2,3-*d*]-pyridazin-8-yl)-2,6-dimethyltetrahydro-2*H*-pyran-4-ol;

or pharmaceutically acceptable salts thereof.

19. The compound according to Claim 18 selected from:
(*S*)-1-(4-(2-hydroxy-4-(trifluoromethyl)phenyl)pyrido[3,4-*d*]pyridazin-1-yl)-3-methylpyrrolidin-3-ol; or a pharmaceutically acceptable salt thereof.

20. The compound according to Claim 18 selected from:
(*S*)-1-(1-(2-hydroxy-4-(trifluoromethyl)phenyl)pyrido[3,4-*d*]-pyridazin-4-yl)-3-methylpyrrolidin-3-ol; or a pharmaceutically acceptable salt thereof.

21. The compound according to Claim 18 selected from:
2-(4-((*cis*)-2,6-dimethylmorpholino)pyridazino[4,5-*d*]pyridazin-1-yl)-5-(trifluoromethyl)phenol; or a pharmaceutically acceptable salt thereof.

22. The compound according to Claim 18 selected from:
(*S*)-1-(5-(2-hydroxy-4-(trifluoromethyl)phenyl)pyrido[2,3-*d*]-pyridazin-8-yl)-3-methylpyrrolidin-3-ol; or a pharmaceutically acceptable salt thereof.

23. The compound according to Claim 18 selected from:
2-(8-((3a*S*,7a*R*)-6-methyloctahydro-1H-pyrrolo[2,3-*c*]pyridin-1-yl)pyrido[2,3-*d*]pyridazin-5-yl)-5-(trifluoromethyl)phenol; or a pharmaceutically acceptable salt thereof.

24. The compound according to Claim 18 selected from:
(2*R*,4*s*,6*S*)-4-(5-(2-hydroxy-4-(trifluoromethyl)phenyl)pyrido[2,3-*d*]-pyridazin-8-yl)-2,6-dimethyltetrahydro-2*H*-pyran-4-ol; or a pharmaceutically acceptable salt thereof.

25. The compound according to Claim 18 selected from:
(2*R*,4*r*,6*S*)-4-(5-(2-hydroxy-4-(trifluoromethyl)phenyl)pyrido[2,3-*d*]-pyridazin-8-yl)-2,6-

dimethyltetrahydro-2*H*-pyran-4-ol; or a pharmaceutically acceptable salt thereof.

26. A pharmaceutical composition comprising a compound of any one of Claims 1 to 25, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

27. A compound according to any one of Claims 1 to 25, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition of Claim 26, for use in the treatment of a disorder, condition, or disease that is responsive to the inhibition of NLRP3 in a mammal in need thereof.

28. The use of a compound of any one of Claims 1 to 25, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition of Claim 26, in the manufacture of a medicament for the treatment, prevention or control of an inflammatory disorder, a fibrotic disorder, a cardiovascular disorder, a metabolic disorder and a neurodegenerative disorder.

29. The use of Claim 28 wherein the disorder is an inflammatory disorder.

30. The use of Claim 29 wherein the inflammatory disorder is selected from: an auto-immune disorder, an auto-inflammatory disorder, an inflammatory joint disorder, an inflammatory skin disorder, and a neuroinflammatory disorder.

31. The use of Claim 28 wherein the disorder is selected from: atherosclerosis, non-alcoholic steatohepatitis, Alzheimers disease and Parkinson's disease.

32. A compound according to any one of Claims 1 to 25, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition of Claim 26, for use in therapy.